- Dec 17, 2017
NCT03151811: Phase 3- Melphalan Flufenamide (Melflufen)-Dex or Pom-dex for RRMM ref. to Len. (OCEAN)
OCEAN NCT03151811: Phase 3: A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to...
209
- Dec 16, 2017
NCT03289299 : Phase 2 - Agg. Smoldering Curative Approach Eval. Novel Therapies & Transplant ASCENT
ASCENT TRIAL Dara-KRd Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT) This study evaluates the...
417
- Dec 16, 2017
NCT03319667: Phase 3 - Isatuximab, Bortezomib, Lenalidomide and Dexamethasone NDMM (IMROZ)
IMROZ Study NCT03319667 Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not...
573
- Dec 15, 2017
NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma
NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma A Safety, PK and Efficacy Study of...
267
- Dec 14, 2017
Phase II HOVON 143 Study: Ixazomib, Dara and Low Dose Dex in Intermediate-Fit Patients NDMM
Phase II HOVON 143 Study Trial Update 63rd ASH Annual Meeting 80 Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit...
278
- Dec 14, 2017
NCT03104842: Phase 2 - GMMG - CONCEPT - Eval. iNduction, Consol. & Maint. Isatuximab Carf Len. & Dex
GMMG - The German Speaking Myeloma Multicenter Group GMMG-CONCEPT trial Isa-KRd NCT03104842: Phase 2 - Evaluation iNduction,...
246